A recent study reveals that patients who discontinue popular GLP-1 drugs like semaglutide or tirzepatide can put back on shed pounds at a significantly accelerated pace than those who end conventional lifestyle regimens.
Published data in a leading medical journal demonstrates that while obese people frequently drop a large proportion of their body weight while undergoing treatment, the mass comes back at an average rate of 0.8 kg per month upon discontinuation.
"People using these drugs should be cognizant of the potential of fast weight regain when the therapy is stopped," stated expert Dr. Susan Jebb.
That rate of recovery means a return to starting weight in about 18 months.
Analyzing Therapies
The research, which looked at dozens of studies involving over 9,000 of participants, contrasted the outcomes of GLP-1 agonists with other pills.
Scientists note that people who shed pounds through diet and exercise typically have a more gradual creep back—perhaps 0.1 kg a month—post-intervention.
Explaining the Quick Regain
Experts suggest the mode of action of the drugs accounts for the accelerated weight return.
GLP-1 drugs imitate a body's own chemical called GLP-1, which controls hunger.
"Artificially providing GLP-1 levels several times higher than normal may cause the body to produce less of its endogenous GLP-1, and may also lessen responsiveness to its actions," noted Dr. Adam Collins, a nutrition expert.
"Withdrawal of this GLP-1 'fix' results in appetite is uncontrolled, making excessive eating a significant risk."
An Ongoing Condition?
Medical guidelines recommend the injections for people with weight-linked medical conditions, alongside recommended diet and exercise modifications.
Many experts contend that, due to the high risk of relapse, the treatment is often long-term.
This view is supported by pharmaceutical companies, who say that the results "highlight the long-term character of obesity," comparing it to managing conditions like diabetes.
Patient Accounts
People who have discontinued the medication report a intense return of appetite.
"It was like something that goes on and I was suddenly extremely hungry," recalled one woman.
This challenge is compounded if patients have not adopted sustainable dietary or behavioural changes during therapy.
Growing Use
Recent estimates indicate that a significant number of people in the UK have used these injections in the last 12 months, with demand being substantial.
- Use is more common among females than men.
- The 40s and 50s demographic shows the greatest usage rates.
- A large proportion access the drugs through private healthcare rather than public health services.
Finally, experts stress that while GLP-1 drugs are potent tools for shedding pounds, they are not a standalone cure and maintained weight loss hinges on integrated behavioural changes.
